Suggested remit: To appraise the clinical and cost effectiveness of melphalan flufenamide with dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma
Following on from information provided to NICE by the company in December 2021, the appraisal of Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 3862

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 December 2022 Discontinued. Following on from information provided to NICE by the company in December 2021, the appraisal of Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
24 December 2021 Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma. Following discussion with the company, NICE has agreed to suspend this technology appraisal from the current work programme and updated timelines are to be confirmed. NICE will continue to monitor the situation and will update interested parties as and when the situation changes.
16 November 2021 Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma has now been rescheduled into the work programme. The appraisal is due to start early March 2022 and will be discussed at committee in early November 2022. The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.
16 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
12 February 2021 - 12 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 March 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2021 when we will write to you about how you can get involved.
05 December 2017 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual